AlphAIalphai — Financial news for AI agents
BenzingaOCT 33 min read$CHRS

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Coherus Oncology (NASDAQ:CHRS)

REDWOOD CITY, Calif., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Coherus Oncology, Inc. ( NASDAQ:CHRS ) , today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer ( SITC ) being held November 5-9, 2025, in National Harbor, Maryland.

Original reporting
Benzinga · Globe Newswire
Published Oct 3, 2025, 1:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 3, 2025, 2:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Coherus Oncology (NASDAQ:CHRS) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$CHRSBullishMed
01

Why it matters

Such presentations often serve as catalysts for stock movement, especially if data is favorable.

02

Market read

The event is highly relevant for biotech investors focusing on immunotherapy developments.

03

What to watch

Market may have already priced in expectations; unexpected negative news could offset potential gains.

Timing: High, as the conference is scheduled for November 5-9, 2025.

Background

Coherus Oncology is advancing its immunotherapy pipeline, with upcoming data presentations at major conferences.

Company-level read

Ticker impact

$CHRSBullishMedium confidence
Context

High relevance due to upcoming conference presentation.

Expected impact

Moderate upward movement in the short term, contingent on the reception of the presentation.

Evidence & confidence

While the event indicates ongoing research activity, the direct impact on stock price depends on the content and market perception.

Market effects

Sector

Potential positive sentiment for biotech and immunotherapy sectors.

Regional

Limited to US markets with biotech exposure.

Global

Moderate, as the event is internationally recognized but primarily US-focused.

Counterpoint

What could challenge this read

The presentation may not yield significant new information, leading to limited price movement.

Key entities

  • Company
    Coherus Oncology

    Biotech firm specializing in immunotherapy and oncology treatments.

  • Organization
    Society for Immunotherapy of Cancer (SITC)

    Leading professional society hosting annual meetings for immunotherapy research.

Read at source← All news

Related articles

AUG 13
$CHRSMedAI 8/10

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.

fool.com6 min
AUG 7
$CHRSMed

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.

yahoo.com6 min
AUG 5
$CHRSMed

Coherus Oncology, Inc. (CHRS): Results of Operations and Financial Condition

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 chrs-20260805xex99d1.htm EX-99.1 Exhibit 99.1 ​ Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update ​ – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – ​ – Clinical data continue to mature across programs with

SEC EDGAR 8-K6 min
AUG 18
$RKLBMedAI 8/10

Rocket Lab Now Prime and Bus Supplier in GEO: Viasat Selects Lightning-GEO for Anti-Jam Satellite

Rocket Lab was selected by Viasat to supply the satellite bus for Viasat’s U.S. Space Force anti-jam Protected Tactical SATCOM-Global (PTS-G) Swarm 1 spacecraft, using Rocket Lab’s Lightning-GEO platform. Viasat will integrate, operate, and lead the prime role; Rocket Lab builds the bus. The Swarm 1 delivery order totals about $437.7M across contractors; terms were not disclosed.

techtimes.com7 min
AUG 17
$LHXMed

L3Harris ousts CEO Kubasik over conduct violation

L3Harris Technologies said CEO Christopher Kubasik stepped down after a board investigation found misconduct and the company entered a separation agreement. The company did not disclose details, saying the conduct was unrelated to financial reporting or operations. Sam Mehta was named successor. Reuters reported no severance, but he can keep vested options. LHX shares fell.

foxbusiness.com3 min